Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617981 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase 3 study of Hepatocellular Carcinoma, sponsored by Imunon.
- Completed
- Registry status
- Phase 3
- Development phase
- 701
- Enrollment target
- 20
- Study locations
NCT00617981 is a Phase 3 study of Hepatocellular Carcinoma that has completed, run by Imunon. The registered enrollment target is 701 participants, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (177% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT00617981, a Phase 3 study of Hepatocellular Carcinoma, has completed, sponsored by Imunon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 701 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency ablation (RFA).
Conditions Studied
Interventions
- DRUG ThermoDox
- DRUG 5% Dextrose Solution
Study Locations (20)
Pennsylvania
- Temple University Hospital - Philadelphia
- Geisinger Health System - Wilkes-Barre
Jiangsu
- Nanjing Drum Tower Hospital, The Affilitated Hospital of Nanjing University Medical School - Nanjing
- The First Affiliated Hospital of Suzhou University - Suzhou
Other
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences - Beijing
- Beijing Cancer Hospital, Peking University School of Oncology - Beijing
California
- UCLA - Los Angeles
Florida
- Mayo Clinic - Jacksonville, Florida - Jacksonville
Kentucky
- University Of Louisville - Louisville
Minnesota
- Mayo Clinic - Rochester
New York
- Mount Sinai School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 701 participants |
| Start Date | 2008-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00617981
The ClinicalTrials.gov registry entry for NCT00617981 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 701 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 253-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (177% higher). The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which ThermoDox is the first listed.
NCT00617981 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Pennsylvania, Jiangsu, Other.
Frequently Asked Questions
What is clinical trial NCT00617981 about?
NCT00617981 is a clinical study titled "Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)". The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when used in conjunction with radiofrequency ablation (RFA).
What is the current status of trial NCT00617981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 701 participants. The study started on 2008-05. Estimated completion is 2016-08.
What conditions does trial NCT00617981 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00617981?
The interventions under investigation include: ThermoDox (DRUG), 5% Dextrose Solution (DRUG).
Who is sponsoring clinical trial NCT00617981?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00617981 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RECRUITING · Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
RECRUITING · Phase 3
-
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ACTIVE NOT RECRUITING · Phase 3
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.